|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
|
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Operating expenses | ||||
| Selling, general and administrative | ||||
| Impairment of ENTADFI | ||||
| Research and development | ||||
| Impairment of ENTADFI assets | ||||
| Impairment of intangibles | ||||
| Impairment of goodwill | ||||
| Impairment of deposit on asset purchase agreement | ||||
| Total operating expenses | ||||
| Loss from operations | ||||
| Other (expense) income | ||||
| Loss on extinguishment of note payable | ||||
| Change in fair value of contingent warrant liability | ||||
| Interest expense - related party | ||||
| Loss on issuance of preferred stock and warrants | ||||
| Loss on extinguishment of preferred stock | ||||
| Interest expense – related party | ||||
| Interest expense | ||||
| Interest income | ||||
| Change in fair value of subscription agreement liability | ||||
| Change in fair value of contingent warrant liabilities | ||||
| Change in fair value of Series D Warrant Liability | ||||
| Change in fair value of Series D Derivative Liability | ||||
| Change in fair value of Series E Warrant Liability | ||||
| Change in fair value of Series E Derivative Liability | ||||
| Gain on forgiveness of accounts payable | ||||
| Other income | ||||
| Loss before income taxes | ||||
| Total other income (expense) | ||||
| Loss before income taxes | ||||
| Income tax (expense) benefit | ||||
| Net loss | ||||
| Foreign currency translation | ||||
| Change in pension benefit obligation | ||||
| Total comprehensive loss | ||||
| Deemed dividend Series C preferred stock | ||||
| Net loss applicable to common stockholders | ||||
| Net loss per share, basic and diluted (in Dollars per share) | ||||
| Net loss per share, diluted (in Dollars per share) | ||||
| Weighted average number of common shares outstanding, basic and diluted (in Shares) | ||||
| Weighted average number of common shares outstanding, diluted (in Shares) | ||||
Loading...